Skip to main content

3 Result(s)

within Hiroshi Kamiyama Remove this filter Oncology Remove this filter

and

  1. No Access

    Article

    Metronomic treatment of malignant glioma xenografts with irinotecan (CPT-11) inhibits angiogenesis and tumor growth

    Irinotecan (CPT-11) has shown emerging promise in the treatment of malignant gliomas. It is believed the mechanism of action of irinotecan is to sensitize glioma cells to the cytotoxic action of radiation ther...

    Shingo Takano, Hiroshi Kamiyama, Ryota Mashiko, Satoru Osuka… in Journal of Neuro-Oncology (2010)

  2. No Access

    Article

    Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1α)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells

    Inhibition of angiogenesis is an important new treatment modality for malignancies, including gliomas. Vascular endothelial growth factor (VEGF) and hypoxia inducible factor-1α (HIF-1α) have been investigated...

    Hiroshi Kamiyama, Shingo Takano, Koji Tsuboi… in Journal of Cancer Research and Clinical On… (2005)

  3. No Access

    Article

    Angiogenesis and antiangiogenic therapy for malignant gliomas

    Angiogenesis is crucial to the growth of malignant gliomas. Therefore, antiangiogenic therapy represents a new, promising therapeutic modality for malignant gliomas. This study was designed to define the malig...

    Shingo Takano, Hiroshi Kamiyama, Koji Tsuboi, Akira Matsumura in Brain Tumor Pathology (2004)